Drug products: Glipizid Meda, Mindiab, Mindiab®
ATC code: A10BB07
Glipizide is used for treatment of type-2 diabetes when lifestyle-modifying treatment is insufficient.
Some studies indicate that women have a higher risk of hypoglycemia during antidiabetic treatment than men.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of glipizide have been found.
No studies with a clinically relevant sex analysis regarding the effects of glipizide have been found.
The ACCORD study (Action to Control Cardiovascular Risk in Diabetes) was a randomized, controlled trial designed to test the effect of intensive glucose control compared with standard control on cardiovascular outcomes in patients with type 2 diabetes. The study showed that women had a higher risk of hypoglycemia than men regardless of treatment .The risk of hypoglycemia in patients treated with a combination of metformin and glipizide or sitagliptin was evaluated in a German study (694 men, 478 women). In patients treated with metformin and glipizide, more women experienced confirmed or severe hypoglycemia than men .
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2014-05-14
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson